ArticleHealth science reports2026
Targeted Interventions in HAM/TSP: Emerging Therapies and Future Directions - A Narrative Review.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Human T-Lymphotropic virus type 1 (HTLV-1) infection can lead to HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), a debilitating chronic neurological disease characterized by progressive lower limb spasticity and autonomic dysfunction. Because the exact disease pathogenesis remains unclear and current management options have limited efficacy, there is a critical need for more effective therapies to reduce morbidity and mortality. This narrative review aims to review the available and diverse range of emerging treatment approaches for HAM/TSP. Methods: A comprehensive narrative review of the existing literature was conducted to assess current treatment methods, historical treatment efforts, and modern therapeutic interventions. The scope includes pharmacological, immunological, targeted, and non-pharmacological strategies aimed at disease management. Results: Current disease-modifying therapies primarily rely on immunomodulatory agents, such as corticosteroids and interferon-alpha, to mitigate neuroinflammation and preserve motor function, whereas traditional antiretroviral therapies demonstrate limited clinical efficacy. Emerging targeted therapies, notably the monoclonal antibody mogamulizumab, show significant promise in reducing HTLV-1-infected cells and sustaining a decrease in spinal cord inflammation. Furthermore, comprehensive care must integrate treatments targeting specific cellular signaling pathways alongside vital non-pharmacological interventions, such as physical rehabilitation and psychological support. Conclusion: The effective management of HAM/TSP necessitates a holistic, multidisciplinary approach encompassing targeted pharmacotherapy, symptomatic management, and psychosocial support. While novel interventions and disease-modifying therapies offer promising new directions, further high-quality, randomized clinical trials are essential to establish standard regimens, optimize dosages, and ensure long-term efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.